63 / 69
63
cytogenetic responses and high transformation-free
survival rates in chronic phase chronic myeloid leukemia
patients
with
resistance,
suboptimalresponse
or
intolerance to imatinib. Haematologica 2010;95:232-40.
64.
Koren-Michowitz M, le Coutre P, Duyster J, Scheid C,
Panayiotidis P, Prejzner W, et al. Activity and tolerability
of nilotinib: a retrospective multicenter analysis of chronic
myeloid leukemia patients who are imatinib resistant or
intolerant. Cancer 2010;116:4564-72.
65.
Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena
G, Palandri F, et al. Nilotinib (formerlyAMN107), a highly
selective BCR-ABL tyrosine kinase inhibitor, is effective
inpatients with Philadelphia chromosome-positive chronic
myelogenous leukemia inchronic phase following imatinib
resistance and intolerance. Blood 2007;110:3540-6.
66.
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson
RA, Gattermann N, et al. Nilotinibis effective in patients
with chronic myeloid leukemia in chronic phase
afterimatinib resistance or intolerance: 24-month follow-up
results. Blood 2011;117:1141-5.
67.
Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A,
et al. Nilotinib is active in chronic and accelerated phase
chronic myeloid leukemiafollowing failure of imatiniband
dasatinib therapy. Leukemia 2010;24:1299-301.
68.
Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-
Passerini C, Baccarani M, Kim DW, et al. Bosutinib is
active in chronic phase chronic myeloid leukemia after
imatinib anddasatinib and/or nilotinib therapy failure.
Blood 2012;119:3403-12.
69.
Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P,
Berneman Z, et al. Prevalence, determinants, and
outcomes of nonadherence to imatinib therapy in patients
with chronic myeloid leukemia: the ADAGIO study. Blood
2009;113:5401-11.